Moderna raises its revenue outlook - but all eyes are on what happens next with its cancer vaccine

Morningstar · 2026-11-06 15:09 UTC

The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

By Jaimy Lee

The company lifted its sales outlook for the year, saying it now expects revenue to grow as much as 25% in 2026

Moderna's top-selling product is still Spikevax, its mRNA-based COVID-19 vaccine.